Guidelines for the prevention, detection diagnosis and treatment of arterial hypertension;Leitlinien für die prävention, erkennung, diagnostik und therapie der arteriellen hypertonie

Deutsche Medizinische Wochenschrift

Volumn 126, Issue SUPPL. 4, 2001, Pages

  Anlauf, M ^a   Bohm M ^a   Bonner G ^a   Dominiak, P ^a   Faulhaber, H D ^a   Franz, I W ^a   Hayduk, K ^a   Hense, H W ^a   Homuth, V ^a   Kolloch, R ^a   Lauterbach, K W ^a   Maiwald, M ^a   Mann, J ^a   Middeke, M ^a   Motz, W ^a   Philipp, Th ^a   Rascher, W ^a   Ritz, E ^a   Schmieder, R E ^a   Scholze, J ^a   Schrader, J ^a   Schultze Rupp, A ^a   Stolte, P ^a   Unger, Th ^a   Wedler, B ^a   Zidek, W ^a   Hochdruckliga, D ^a   more..

^a Deutsche Hypertonie Gesellschaft   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; LOSARTAN; MOXONIDINE; NIFEDIPINE; VERAPAMIL;

DIAGNOSTIC APPROACH ROUTE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MATERNAL HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLE; TREATMENT INDICATION;

EID: 17144447919     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (292)

1. Leitlinien und evidence-based medicine in Deutschland
2. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data
3. Identification of risk factors in hypertensive patients: Contribution of randomized controlled trials through an individual patient data-base
4. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
5. 1999 World Health Organization-International Society of hypertension guidelines for the management of hypertension
6. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
7. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world
8. Guidelines on preventing cardiovascular disease in clinical practice
9. Population trends in antihypertensive drug use: Results from the MONICA Augsburg Project 1984 to 1995
10. Assessing hypertension management in the community - Trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project Augsburg 1984-1995
11. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
12. Blood pressure and high blood pressure. Aspects of risk
13. Blood-pressure control in the hypertensive population
14. Ambulatory blood pressure monitoring and blood pressure self- measurement in the diagnosis and management of hypertension
15. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel
16. What is the value of home blood pressure measurement in patients with mild hypertension?
17. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan
18. Sektion blutdruckmessung und hochdruckdiagnostik der Deutschen liga zur bekämpfung des hohen blutdruckes e.V. D-H-G: Ambulante 24-h-blutdruckmessung (ABDM)
19. Nocturnal blood pressure in normotensive subjects and those with white coat, primary, and secondary hypertension
20. Sex, cardiac hypertrophy and diurnal blood pressure variations in essential hypertension
21. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy
22. Prognostic value of ambulatory blood pressure measurements: Further analyses
23. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension
24. Prognostic significance of the white coat effect
25. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers
26. Diurnal variations of blood pressure and microalbuminuria in essential hypertension
27. Blood pressure measurement during ergometric stress testing
28. Recommendations and standard guidelines for exercise testing. Report of the Task Force Conference on Ergometry, Titisee 1987
29. Exercise blood pressure predicts cardiovascular mortality in middle-aged men
30. Early prediction of hypertension using exercise blood pressure
31. Follow-up of normotensive men with exaggerated blood pressure response to exercise
32. Exercise testing in assessment of hypertension
33. Left ventricular hypertrophy in mild hypertension: Correlation with exercise blood pressure
34. Exercise systolic blood pressure: A powerful determinant of increased left ventricular mass in patients with hypertension
35. Prognostic significance of exercise blood pressure and heart rate in middle-aged men
36. A clinical prediction rule for renal artery stenosis
37. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: A review of 282 cases
38. Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension
39. Glucocorticoid-remediable aldosteronism
40. Liddle's syndrome
41. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man
42. Severe autosomal dominant hypertension and brachydactyly in a unique Turkish kindred maps to human chromosome 12
43. Neurovascular compression at the ventrolateral medulla in autosomal dominant hypertension and brachydactyly
44. Intersalt: An international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion
45. Definition of «salt sensitivity»
46. Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on Kalzium antagonists
47. Interaction of pharmacological and nonpharmacological therapy
48. Alcohol, hypertension and cardiovascular disease - Implications for management
49. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet
50. Long-term effect of mackerel diet on blood pressure, serum lipids and thromboxane formation in patients with mild essential hypertension
51. Does potassium supplementation lower blood pressure? A meta-analysis of published trials
52. Electrolyte intake and blood pressure: A study in contradictions and controversy
53. Lack of effect of oral magnesium on high blood pressure: A double blind study
54. Effect of magnesium on blood pressure
55. Smoking and hypertension
56. Relation between leisure-time physical activity and blood pressure in older women
57. Exercise training combined with antihypertensive drug therapy. Effects on lipids, blood pressure, and left ventricular mass
58. Exercise: How much is enough, and how much is too much?
59. A pilot study on the long-term effects of combined drug therapy and psychophysiologically-oriented therapy in patients with severe essential hypertension
60. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
61. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
62. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
63. Effect of the angiotensin-converting-enzyme inhibitor Benazepril on the progression of chronic renal insufficiency
64. Survival in treated hypertension: Follow up study after two decades
65. Systolic blood pressure as an independent predictor of mortality in the Hypertension detection and follow-up program
66. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
67. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
68. Discontinuation of doxazosin arm of ALLHAT. Antihypertensive and lipid- lowering treatment to prevent heart attack
69. Treatment concepts in therapy refractory hypertension
70. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis
71. Renal angioplasty: Better for treating hypertension or for rescuing renal function?
72. Epidemiology of heart failure
73. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
74. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension
75. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective
76. Blood pressure and mortality among men with prior myocardial infarction
77. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
78. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
79. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
80. MRC trial of treatment of mild hypertension: Principal results
81. Medical Research Council trial of treatment of hypertension in older adults: Principal results
82. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension
83. Beta-blokkers versus diuretics in hypertensive men: Main results from the HAPPHY trial
84. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS)
85. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies
86. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
87. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
88. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
89. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
90. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
91. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
92. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
93. Shanghai trial of nifedipine in the elderly (STONE)
94. Chinese trial on isolated systolic hypertension in the elderly
95. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting Kalzium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
96. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
97. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
98. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)
99. Randomised trial of effects of Kalzium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
100. For the USC: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
101. Effect of the Kalzium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III
102. Morbidity and mortality of renal dialysis: An NIH consensus conference statement
103. Early referral to the nephrologist and timely initiation of renal replacement therapy: A paradigm shift in the management of patients with chronic renal failure
104. Blood pressure and end-stage renal disease in men
105. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study
106. Similar risks of nephropathy in patients with type I or type II diabetes mellitus
107. Diabetic nephropathy in type II diabetes: Effect of metabolic control and blood pressure on its development and course
108. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients
109. Predictors of mortality in insulin dependent diabetes: 10 Year observational follow up study
110. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study
111. Reduction of blood pressure retards the progression of chronic renal failure in man
112. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension
113. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
114. Group ftCS: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
115. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
116. Prevention of diabetic renal disease with special reference to microalbuminuria
117. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study
118. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease
119. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
120. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide
121. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure
122. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both
123. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
124. Nephrologists neglect administration of betablockers to dialysed diabetic patients
125. Sympathetic overactivity in patients with chronic renal failure
126. Achievement and safety of a low blood pressure goal in chronic renal disease
127. Audit of antihypertensive treatment in patients with renal failure
128. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
129. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
130. Blood pressure and risk of stroke in patients with cerebrovascular disease
131. A multifactorial analysis of risk factors for recurrence of ischemic stroke
132. Post-stroke antihypertensive treatment study. A preliminary result
133. Antihypertensive drugs in very old people: A subgroup meta-analysis of randomised controlled trials
134. Very high blood pressure in acute stroke
135. The changes in blood pressure after acute stroke: Abolishing the 'white coat effect' with 24-h ambulatory monitoring
136. Blood pressure after stroke
137. Blood pressure during the first minutes of focal cerebral ischemia
138. Effect of blood pressure and diabetes on stroke in progression
139. The prognostic value of admission blood pressure in patients with acute stroke
140. Emergency and intensive care treatment after stroke
141. Tissue plasminogen activator for acute ischemic stroke
142. Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men
143. The association between midlife blood pressure levels and late-life cognitive function
144. 15-Year longitudinal study of blood pressure and dementia
145. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
146. Etiology and prevalence of hypertension in diabetic patients
147. I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
148. Diabetic and hypertensive heart failure
149. Diabetes and hypertension: The bad companions
150. The rising tide of endstage renal failure from diabetic nephropathy type II - An epidemiological analysis
151. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
152. Microalbuminuria, blood pressure, metabolic control, and renal involvement. Longitudinal studies in white non-insulin-dependent diabetic patients
153. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients
154. Verbesserte Prognose von Typ-I- und Typ-II-Diabetikern mit Nephropathie
155. II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients
156. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practioner Project
157. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
158. Lack of agreement between the World Health Organization Category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose
159. Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese Population
160. The significance of 24-hour blood pressure monitoring in patients with diabetes mellitus
161. An assessment of blood pressure measurement in a diabetic clinic using random-zero, semi-automated and 24-hour monitoring
162. The stages in diabetic renal disease - With emphasis on the stage of incipient diabetic nephropathy
163. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas
164. Morbidity, mortality, and albuminuria in type 2 diabetic patients: A three-year prospective study of a random Cohort in general practice
165. On the impact of hypertension on the prognosis of NIDDM. Results of the Schwabing GP-Program
166. A Desktop Guide to Type 1 (Insulin-dependent) Diabetes Mellitus: European Diabetes Policy Group 1998, International Diabetes Federation, European Region
167. Blood pressure elevation in diabetes: The results from 24-h ambulatory blood pressure recordings
168. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
169. Effects of Kalzium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
170. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
171. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM
172. Systolic blood pressure determines the rate of decline of glomerular filtration rate in Type 2 (non-insulin-dependent) diabetes mellitus
173. The diabetes control and complications trial research group
174. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial - The hypertension control program
175. Sodium restriction and blood pressure in hypertensive type II diabetics: Randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation
176. Comparison of the hypotensive and metabolic effects of metoprolol therapy with a high fibre, low sodium, low fat diet in hypertensive type 2 diabetic subjects
177. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy
178. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria
179. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM
180. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension
181. Group NICS: Prospective randomized multicentre trial of effect of protein restriction on progression of chronic renal insufficiency
182. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function
183. Recommendations for the nutritional management of patients with diabetes mellitus
184. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study
185. General mangement of end stage renal disease
186. Improved survival in patients with diabetic nephropathy
187. Prognosis in diabetic nephropathy
188. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
189. Timolol treatment after myocardial infarction in diabetic patients
190. Diabetic patients and beta-blockers after acute myocardial infarction
191. Management of dyslipidemia in adults with diabetes
192. Insulin resistance and hypertension: Connections with sodium metabolism
193. Hypertension during reduction of long-term steroid therapy in young subjects with asthma
194. Airway responsiveness and cough induced by angiotensin converting enzyme inhibition
195. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough
196. Daytime hypertension in obstructive sleep apnea. Prevalence and contributing risk factors
197. Undiagnosed sleep apnea in patients with essential hypertension
198. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model
199. The prevalence of obstructive sleep apnea in hypertensives
200. Population-based study of sleep-disordered breathing as a risk factor for hypertension
201. Obstructive sleep apnea syndrome in male hypertensives, refractory to drug therapy. Nocturnal automatic blood pressure measurements - An aid to diagnosis?
202. Influence of sleep apnea on 24-hour blood pressure
203. The first report of the Systolic and Pulse Pressure (SYPP) working group
204. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction
205. Increased pulse pressure and risk of heart failure in the elderly
206. National high blood pressure education program working group
207. Isolated systolic hypertension: Prognostic information provided by pulse pressure
208. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction
209. The role of diastolic blood pressure when treating isolated systolic hypertension
210. Refractory hypertension
211. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial
212. Randomised trial of treatment of hypertension in elderly patients in primary care
213. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
214. Treatment of hypertension in the elderly
215. Trial of Nonpharmacologic Intervention in the Elderly (TONE). Design and rationale of a blood pressure control trial
216. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: Results from phase 1 of the Trials of Hypertension Prevention
217. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study
218. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study
219. Treatment with Kalzium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-European population: Results from STEPHY II. Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly
220. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The CAPPP randomised trial
221. Hypertensive schwangerschaftserkrankungen
222. National high blood pressure education program - Working group report on high blood pressure in pregnancy
223. The classification and definition of the hypertensive disorders of pregnancy
224. Untersuchungen zur klinik und differenzialtherapie der milden hypertonie in der schwangerschaft
225. Pregnancy outcome in 211 patients with mild chronic hypertension
226. A multivariate analysis of risk factors for preeclampsia
227. Genetics of hypertension in pregnancy: Possible single gene control of pre-eclampsia and eclampsia in the descendants of eclamptic women
228. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Subsequent pregnancy outcome and long-term prognosis
229. Epidemiology of pregnancy-induced hypertension
230. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension
231. Hypertension in pregnancy: Clinical-pathological correlations and remote prognosis
232. Preeclampsia in diabetic pregnancies
233. The antiphospholipid syndrome and pregnancy
234. The factor V Leiden mutation may predispose women to severe preeclampsia
235. Pre-eclampsia: More than pregnancy-induced hypertension
236. Gestation in women with kidney disease: Prognosis and management
237. Effects of hypertension on pregnancy monitoring and results
238. Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy
239. Blood pressure self-monitoring during pregnancy: Practical considerations
240. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: Which is the better predictor of severe hypertension?
241. Arbeitsgemeinschaft schwangerschaftshochdruck/gestose: Empfehlungen für diagnostik und therapie bei bluthochdruck in der schwangerschaft
242. Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy
243. Fortnightly review: Management of hypertension in pregnancy
244. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies
245. Management of severe pre-eclampsia and eclampsia by UK consultants
246. Hypertensive disorders of pregnancy
247. Treatment of hypertension in patients with pre-eclampsia: A prospective parallel-group study comparing dihydralazine with urapidil
248. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia
249. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial
250. The combination of magnesium sulphate and nifedipine: A cause of neuromuscular blockade
251. Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia
252. Low sodium diet and pregnancy-induced hypertension: A multi-centre randomised controlled trial
253. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women
254. Effect of Kalzium supplementation on pregnancy-induced hypertension and preeclampsia: A meta-analysis of randomized controlled trials
255. Kalzium supplementation during pregnancy: A systematic review of randomised controlled trials
256. Trial of Kalzium to prevent preeclampsia
257. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis
258. Risks and benefits of beta-receptor blockers for pregnancy hypertension: Overview of the randomized trials
259. Evaluation of Kalziumant-agonist (Nifedipine) in the treatment of pre-eclampsia
260. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term
261. Randomized comparison of Kalzium antatgonists and beta-blokkers in the treatment of pregnancy-induced hypertension
262. Overview of randomised trials of diuretics in pregnancy
263. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development
264. Toxicokinetic analysis of losartan during gestation and lactation in the rat
265. Arzneiverordnung in der schwangerschaft und stillzeit
266. Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants
267. Transplacental passage and breast milk concentrations of hydralazine
268. Atenolol in human plasma and breast milk
269. To nurse when receiving acebutolol: Is it dangerous for the neonate?
270. Toxic effects of atenolol consumed during breast feeding
271. Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine of mothers and offspring
272. Nifedipine transfer into human milk
273. Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement
274. The excretion of enalapril and enalaprilat in human breast milk
275. Blood pressure in childhood: Pooled findings of six European studies
276. Pediatric hypertension
277. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program
278. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: A multicenter trial including 1141 subjects
279. Hypertension in children
280. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery)
281. Treatment of hypertension in the perioperative patient
282. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery
283. Risk of gastrointestinal haemorrhage with Kalzium antagonists in hypertensive persons over 67 years old
284. Use of Kalzium antagonists and need for perioperative transfusion in older patients with hip fracture: Observational study
285. Cost benefit of treating hypertension
286. Pharmaökonomie. Ebenen der gesundheitsökonomischen bewertung von arzneimitteln
287. Cost-minimization and the number needed to treat in uncomplicated hypertension